Supernus Pharmaceuticals (SUPN) News Today $48.35 +0.39 (+0.81%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$48.66 +0.31 (+0.63%) As of 10/3/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street ZenOctober 3 at 12:30 AM | marketbeat.comCEO’s Strategic Stock Sale: What It Means for Supernus PharmaceuticalsOctober 3 at 10:10 PM | tipranks.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 3 at 6:42 PM | marketbeat.comCEO’s Major Stock Sale Shakes Up Supernus PharmaceuticalsOctober 2 at 10:11 PM | tipranks.comSupernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation?October 2 at 7:10 PM | finance.yahoo.comCantor Fitzgerald Increases Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $63.00October 2 at 2:51 AM | americanbankingnews.comCantor Fitzgerald Maintains Supernus Pharmaceuticals (SUPN) Overweight RecommendationOctober 1, 2025 | msn.comJack Khattar Sells 10,235 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) StockOctober 1, 2025 | insidertrades.comSupernus Pharmaceuticals CEO Makes Significant Stock Sale!September 30, 2025 | tipranks.comInsider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells 10,235 Shares of StockSeptember 30, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Given New $63.00 Price Target at Cantor FitzgeraldSeptember 30, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Sets New 52-Week High - Time to Buy?September 29, 2025 | marketbeat.comPharma ETFs In A Tariff Storm: How Investors Can Hedge RiskSeptember 29, 2025 | benzinga.comBranded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)September 25, 2025 | msn.comInsider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells 29,513 Shares of StockSeptember 25, 2025 | insidertrades.comJack Khattar Sells 29,513 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) StockSeptember 24, 2025 | marketbeat.comJack Khattar Sells 16,587 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) StockSeptember 24, 2025 | insidertrades.comStrs Ohio Acquires Shares of 11,000 Supernus Pharmaceuticals, Inc. $SUPNSeptember 24, 2025 | marketbeat.comCEO’s Major Stock Sale Shakes Up Supernus PharmaceuticalsSeptember 23, 2025 | tipranks.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $779,920.74 in StockSeptember 23, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month High - Time to Buy?September 22, 2025 | marketbeat.comWedge Capital Management L L P NC Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 22, 2025 | marketbeat.comVoya Investment Management LLC Buys 16,786 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 22, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Zacks Research to Strong-Buy RatingSeptember 20, 2025 | marketbeat.comSupernus Pharmaceuticals: Heading In The Right DirectionSeptember 17, 2025 | seekingalpha.comSupernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells $229,350.00 in StockSeptember 16, 2025 | marketbeat.com3 Reasons to Avoid SUPN and 1 Stock to Buy InsteadSeptember 16, 2025 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) SVP Frank Mottola Sells 5,000 SharesSeptember 16, 2025 | insidertrades.comRhumbline Advisers Sells 7,121 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 15, 2025 | marketbeat.comVillanova Investment Management Co LLC Has $641,000 Stock Position in Supernus Pharmaceuticals, Inc. $SUPNSeptember 13, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Sold by Great Lakes Advisors LLCSeptember 12, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in StockSeptember 11, 2025 | marketbeat.comAxiom Investors LLC DE Sells 15,521 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 11, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 55,578 SharesSeptember 10, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - Here's WhySeptember 10, 2025 | marketbeat.comCEO’s Major Stock Sale Shakes Up Supernus PharmaceuticalsSeptember 9, 2025 | tipranks.comCan Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?September 9, 2025 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $2,557,143.78 in StockSeptember 9, 2025 | insidertrades.comUnpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals StocksSeptember 8, 2025 | finance.yahoo.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Cut by PDT Partners LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Raised by Cubist Systematic Strategies LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - What's Next?September 4, 2025 | marketbeat.comTrexquant Investment LP Has $4.73 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Armistice Capital LLCSeptember 2, 2025 | marketbeat.comNorthern Trust Corp Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 2, 2025 | marketbeat.com2 Healthcare Stocks on Our Watchlist and 1 We AvoidSeptember 1, 2025 | uk.finance.yahoo.comAshford Capital Management Inc. Purchases 20,781 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 1, 2025 | marketbeat.comPiper Sandler Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $40.00August 31, 2025 | marketbeat.comHsbc Holdings PLC Sells 180,627 Shares of Supernus Pharmaceuticals, Inc. $SUPNAugust 31, 2025 | marketbeat.comFrank Mottola At Supernus Pharmaceuticals Capitalizes: Options Exercised, Resulting In $448KAugust 30, 2025 | benzinga.com Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUPN Media Mentions By Week SUPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.370.54▲Average Medical News Sentiment SUPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼157▲SUPN Articles Average Week Get the Latest News and Ratings for SUPN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Supernus Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CORT News JAZZ News PRGO News PCRX News NKTR News OMER News ASMB News CPIX News LLY News JNJ News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
